Alexion Pharmaceuticals, Inc. announced today that the National Institute for Health and Clinical Excellence Highly Specialised Technologies Evaluation Committee has reaffirmed the very significant clinical value of eculizumab for the treatment of atypical hemolytic uremic syndrome and the lack of other effective therapies, and has issued a recommendation that it be nationally commissioned for all patients suffering from this severe and life-threatening genetic disorder.